



## 10 common mistakes in clinical mycology

**Dr Atul Patel, MD, FIDSA**

Chief Consultant and Director  
Infectious Diseases Clinic  
Vedanta Institute of Medical Sciences  
Ahmedabad, India



Presented at MMTN 20-21 July 2019.  
© Copyright of speaker. All rights reserved.

# 10 Common Mistakes in Clinical Mycology

ATUL K PATEL MD, FIDSA

Ahmedabad

## Disclaimer

Based on few of the mistakes that I did in my initial practice and few I observed from other colleagues.

1: Clinicians forget to request direct microscopy (KOH, Calcoflaur white stain) from biological sample



Common mistake



Mainly due to lack of clinical suspicion




Under estimate value of direct microscopy



Direct microscopy has an immense value, rapid turn around time is 1 hour: tell you about which antifungal

## Brain Biopsy

Direct microscopy of brain lesion show  
CSF examination: WNL



IV Voriconazole started,  
Blood culture grew *Klebsiella Pneumoniae*: Colistin + Meropenem

## 2: Fungal culture is not requested from biological sample



This is very common, especially in a patient with FUO, constitutional symptoms, weight loss with lymphadenopathy +/- Adrenal enlargement





TB is suspected and biopsy invariably sent for GenXpert MTB/RIF, TB Culture and histopathology



Histoplasmosis is missed unless histopathologist identify yeast in tissue on H&E stain

# CT Scan: Abdomen



### 3: Not looked for drug-drug interactions

Drug-Drug interactions affects efficacy of antifungal agents or end up in a life threatening ADR

#### Common examples

- Patient receiving Rifampicin containing anti TB and diagnose with fungal infections: Started on Voriconazole/ Fluconazole/Caspofungin
- Patient is receiving Itraconazole and receiving acid reducing agents (Ranitidine, Pantoprazole etc)
- Patient is on Amiodarone, warfarin and started on Fluconazole/Voriconazole

### 4: Concomitant Nephrotoxic agents

Concomitant Aminoglycosides/ Polymyxin or other nephrotoxic agents are overlooked in a patients receiving Amphotericin antifungal treatment

5: Failed to adjust antifungal dosage according to renal replacement therapy

This is important for patients receiving Fluconazole

Common when patient is receiving intermittent hemodialysis

6: QTc monitoring is not done in ICU patients on Azole antifungals

This is important for patients receiving Azole

Concomitant hypomagnesemia, quinolones, clarithromycine and other drugs with potential effect on QTc prolongation

End up with life threatening arrhythmias, sudden cardiac death

## 7: TDM is not performed

This is important for patients receiving Voriconazole, Posaconazole, Itraconazole

Clinicians believe that using recommended weight based dosage of antifungals and TDM may not be required

End up with either treatment failure/drug toxicities

## 8: Clinicians using Symp. Posaconazole as a first line treatment for Mucormycosis

Sy. Posa will take 7 days to achieve steady state level

Mucormycosis is a life threatening angio-invasive infection, delay in effective therapy contribute to morbidity and mortality

In Ampho intolerant patients, overlap Posa for 1 week, check the trough level

IV/Tablet Posa could be an option for intolerant to Ampho

## 9: Voriconazole/Echinocandins for non albicans candida urinary infection



Isolation of Candida in urine is not uncommon




Antifungal penetration to urinary system

## 10: Antifungal treatment to patients BAL culture positive for candida

Candida pneumonia is uncommon/rare

Candida is generally a coloniser





Thank You

Presented at MMTN 21 July 2019.  
© Copyright of speaker. All rights reserved.